91 results on '"Arhin, Francis"'
Search Results
52. Antibacterial Activity of Oritavancin and Daptomycin Against Clinical Isolates of Vancomycin-Resistant Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models
53. Assessment of the Propensity of Oritavancin to Induce Susceptibility Changes Among Staphylococcus aureus Nasal Carriage Isolates in a Phase 2 study in Patients with Acute Bacterial Skin and Skin Structure Infections
54. Assessment of Oritavancin Activity in Combination with Beta-Lactams against Vancomycin-Resistant Enterococci
55. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus
56. Use of In Vitro Vancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide
57. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis
58. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005–2008
59. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)
60. Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureus Infection
61. Correlation between oritavancin and vancomycin minimum inhibitory concentrations in staphylococci
62. Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
63. Assessment of Oritavancin Serum Protein Binding across Species
64. Characterization of the In Vitro Activity of Novel Lipoglycopeptide Antibiotics
65. Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates
66. Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
67. Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus
68. Inhibition of Transcription inStaphylococcus aureusby a Primary Sigma Factor-Binding Polypeptide from Phage G1
69. Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci
70. Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro
71. Bisphosphonated Benzoxazinorifamycin Prodrugs for the Prevention and Treatment of Osteomyelitis
72. Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis
73. Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus
74. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters
75. Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing
76. Antimicrobial drug discovery through bacteriophage genomics
77. Triaminotriazine DNA helicase inhibitors with antibacterial activity
78. Comparative In VitroActivities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureusIsolates in a Nondividing State
79. Sequencing ofporAfrom clinical isolates ofNeisseria meningitidisdefines a subtyping scheme and its genetic regulation
80. Porins of Haemophilus influenzae Type b Mutated in Loop 3 and in Loop 4
81. Subtyping ofNeisseria meningitidisstrains isolated in Quebec, Canada: correlation between deduced amino acid sequences and serosubtyping techniques
82. Use of In VitroVancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide
83. Organization of the genes encoding p-aminobenzoic acid synthetase from Streptomyces lividans 1326
84. Antimicrobial drug discovery through bacteriophage genomics.
85. Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In VitroPharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureusInfection
86. Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureusCells In Vitro
87. Oritavancin Disrupts Membrane Integrity of Staphylococcus aureusand Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
88. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureusnasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections
89. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faeciumIsolates with or without Reduced Susceptibility to Daptomycin in an In VitroPharmacokinetic/Pharmacodynamic Model
90. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faeciumIsolates in an In VitroPharmacokinetic/Pharmacodynamic Model of Infection
91. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.